Company Event • 20 Aug 2026 13:45 • Upcoming
Add To Calendar
Q2 2026
Company Event • 13 May 2026 13:30 • Upcoming
Add To Calendar
Q1 2026
Company Event • 01 Sep 2025 22:20 • Latest
DNB Carnegie Småbolagsdag
No more events
𝛼SK or SearchENTITY
Alzinova (ALZ SS)
Alzinova (ALZ SS)
15
Analysis
Health Care • Sweden
Alzinova AB is a Swedish clinical-stage biopharma company that develops immunotherapies for the treatment of Alzheimer's disease. Its lead product candidate is ALZ-101, a therapeutic vaccine for Alzheimer's that has completed a phase 1b study. The company is also developing ALZ-201, a monoclonal antibody that targets and neutralizes the neurotoxic forms of the peptide Aß42, known as oligomers, which are considered a primary cause of Alzheimer's disease.
morex